Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-0-12-3544-3939
Debt
Debt-to-Equity RatioN/A
Current Ratio1.83
Quick Ratio1.83
Price-To-Earnings
Trailing P/E Ratio-3.07
Forward P/E Ratio-1.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$36.07 million
Price / Sales0.86
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book2.41
Profitability
EPS (Most Recent Fiscal Year)($0.75)
Net Income$-9,280,000.00
Net Margins-33.36%
Return on Equity-105.24%
Return on Assets-17.79%
Miscellaneous
Employees60
Outstanding Shares13,840,000
Market Cap$31.56 million
SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions
What is SUMMIT THERAPEU/S's stock symbol?
SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."
How were SUMMIT THERAPEU/S's earnings last quarter?
SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its earnings results on Tuesday, June, 5th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.76) by $0.21. The business had revenue of $5.33 million for the quarter, compared to analysts' expectations of $6.48 million. SUMMIT THERAPEU/S had a negative net margin of 33.36% and a negative return on equity of 105.24%. View SUMMIT THERAPEU/S's Earnings History.
What price target have analysts set for SMMT?
9 equities research analysts have issued twelve-month price targets for SUMMIT THERAPEU/S's stock. Their forecasts range from $3.00 to $33.00. On average, they anticipate SUMMIT THERAPEU/S's stock price to reach $14.7143 in the next year. This suggests a possible upside of 556.9% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.
What is the consensus analysts' recommendation for SUMMIT THERAPEU/S?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.
Who are some of SUMMIT THERAPEU/S's key competitors?
Some companies that are related to SUMMIT THERAPEU/S include MOTIF BIO PLC/S (MTFB), VBI Vaccines (VBIV), Catalyst Biosciences (CBIO), BioXcel Therapeutics (BTAI), CTI BioPharma (CTIC), Forward Pharma A/S (FWP), Aptevo Therapeutics (APVO), Aerpio Pharmaceuticals (ARPO), Oncolytics Biotech (ONCYF), Arcturus Therapeutics (ARCT), Iterum Therapeutics (ITRM), BIOLINERX Ltd/S (BLRX), Vernalis (VNLPY), XBiotech (XBIT) and GT Biopharma (GTBP).
Who are SUMMIT THERAPEU/S's key executives?
SUMMIT THERAPEU/S's management team includes the folowing people:
- Mr. Glyn O. Edwards, CEO & Exec. Director (Age 62)
- Mr. Erik Ostrowski, Chief Financial Officer (Age 45)
- Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 52)
- Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)
- Ms. Michelle Avery, Director of Investor Relations
When did SUMMIT THERAPEU/S IPO?
(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.
Who are SUMMIT THERAPEU/S's major shareholders?
SUMMIT THERAPEU/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (5.25%), Renaissance Technologies LLC (0.79%) and Acadian Asset Management LLC (0.77%).
Which major investors are selling SUMMIT THERAPEU/S stock?
SMMT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Point72 Asset Management L.P..
Which major investors are buying SUMMIT THERAPEU/S stock?
SMMT stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
How do I buy shares of SUMMIT THERAPEU/S?
Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SUMMIT THERAPEU/S's stock price today?
One share of SMMT stock can currently be purchased for approximately $2.24.
How big of a company is SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S has a market capitalization of $31.56 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. SUMMIT THERAPEU/S employs 60 workers across the globe.
What is SUMMIT THERAPEU/S's official website?
How can I contact SUMMIT THERAPEU/S?
SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-0-12-3544-3939 or via email at [email protected]
MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)
MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
